Cost Curve

Democrats Lay Out a Litany of Price-Lowering Ideas for Drugs (But Fail to Ask the Most Important Question)

And the Trump administration moves ahead with MFN rules as European governments weigh the impacts

Brian Reid

CMS Proposes Codifying Rules for How It Will Run Drug Negotiations

CMS’s efforts include a change to how and when certain blockbusters get Medicare-set prices

Brian Reid

White House Claims a ‘Significant’ Number of Companies Have Elected to Join MFN-in-Medicaid Model

And HHS is taking the next step in transitioning toward a 340B ‘rebate model’

Brian Reid

A Key Deadline for Companies Seeking MFN Deals Has Arrived

And Pfizer’s CEO sends a letter to Germany’s leader: ”We are ​reviewing ... certain planned investments in Germany”

Brian Reid

Politico Says the U.S. and Germany Are In ‘Secret Talks’ About MFN

And PCMA releases a document that is a master class in finger-pointing

Brian Reid

CMS Will Need to Bridge Beyond the ‘Bridge’ Demo to Preserve Long-Term Access to Obesity Meds in Medicare

And I have the numbers on TrumpRx’s web visit numbers for May

Brian Reid

It’s All Obesity Today: Drama at ADA, Pricing Implications for Pfizer’s Med, and WSJ on Shrinking Employer Coverage

Plus: ‘Why would you threaten 50% of your revenue if you think you cannot get a reasonable price in the UK or France?’

Brian Reid

Supreme Court Addresses ‘Skinny Labeling’ for Generic Drugs

And Pfizer’s Impact Report is out, detailing how the company’s portfolio-wide net price shifted in 2025

Brian Reid

An Apex Grab Bag on Value-Based Insurance, Investments in Europe, and Ongoing 340B Battles

Brian Reid